Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2024

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2024

DelveInsight’s, “Peripheral T-cell lymphoma (PTCL) – Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Peripheral T-cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peripheral T-cell lymphoma Understanding

Peripheral T-cell lymphoma (PTCL): Overview

Peripheral T-cell lymphoma is defined as a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. Peripheral T-cell lymphoma is classified as a subtype of non-Hodgkin’s lymphoma (NHL). NHL affects two particular types of white blood cells: B-cells and T-cells. Peripheral T-cell lymphoma specifically affects T-cells, and results when T-cells develop and grow abnormally.

Symptoms

Although the signs and symptoms of Peripheral T-cell lymphomas vary according to the subtype, some common signs and symptoms of the diseases include fatigue, a painless swelling in the neck, armpit or groin (due to an enlarged lymph node), night sweats, rash and weight loss.

Diagnosis

Most Peripheral T-cell lymphomas are diagnosed by taking a small sample (a biopsy) of an enlarged lymph node and then examining the cells under a microscope. Generally, either the lymph node, or a part of the lymph node, is surgically removed so that the hematopathologist has enough tissue to make a firm diagnosis. Lymph node biopsy tissue can often be removed after the administration of a local anesthetic.

Treatment

Peripheral T-cell lymphoma Emerging Drugs Chapters

The standard upfront remains CHOP or CHOP-based therapy for most subtypes. The only upfront treatment that has shown superiority over CHOP, based on a randomized clinical trial, is the combination of brentuximab vedotin (Adcetris) plus cytoxan vincristine and prednisone (CHP) for CD30 expressing Peripheral T-cell lymphoma subtypes. Several single agents are now approved by the Food and Drug Administration for the treatment of relapsed or refractory Peripheral T-cell lymphoma.

Peripheral T-cell lymphoma Emerging Drugs

• HBI-8000: HUYA Bioscience International

The novel epigenetic drug, HBI-8000, is a member of the benzamide class of histone deacetylase inhibitors (HDACIs), working by controlling how tightly DNA is wound around histone proteins, which regulate gene expression. This alters the expression of several proteins involved in processes that arrest the growth of cancer cells, increase tumor immunity and change the tumor microenvironment. Evidence suggests that this mechanism increases the efficacy of other cancer agents such as checkpoint inhibitors.

Further product details are provided in the report……..

Peripheral T-cell lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Peripheral T-cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Peripheral T-cell lymphoma

There are approx. 40+ key companies which are developing the therapies for Peripheral T-cell lymphoma. The companies which have their Peripheral T-cell lymphoma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, HUYA Bioscience International, Shandong New Time Pharmaceutical, Verastem, Genor Biopharma Co., Ltd., Solasia Pharma K.K., CerRx, Inc., Seattle Genetics, Inc. etc.

Phases

DelveInsight’s report covers around 40+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Peripheral T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Intra-tumoral
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibodies
• Immunoglobulins
• Small molecules
• Pyrimidines
• Proteins and Peptides
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral T-cell lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral T-cell lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral T-cell lymphoma drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral T-cell lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral T-cell lymphoma.

Peripheral T-cell lymphoma Report Insights

• Peripheral T-cell lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peripheral T-cell lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peripheral T-cell lymphoma drugs?
• How many Peripheral T-cell lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral T-cell lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral T-cell lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peripheral T-cell lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Acrotech Biopharma LLC
• HUYA Bioscience International
• Seattle Genetics, Inc.
• Akeso Pharmaceuticals, Inc.
• Shandong New Time Pharmaceutical Co., LTD
• Verastem, Inc.
• Genor Biopharma Co., Ltd.
• CerRx, Inc.
• Shanghai YingLi Pharmaceutical Co. Ltd.
• Dizal Pharmaceuticals
• Kura Oncology, Inc.

Key Products

• Pralatrexate Injection
• HBI-8000
• AK104
• SHC014748M
• F520
• Duvelisib
• GB226
• SP-02L
• YY-20394
• AZD4205
• Brentuximab vedotin